Opioid Withdrawal Syndrome

Opioid withdrawal syndrome occurs when opioid-dependent individuals stop or significantly reduce opioid use, due to neuroadaptive changes from chronic opioid use causing rebound noradrenergic hyperactivity (locus coeruleus hyperexcitability) and dopaminergic dysregulation. Withdrawal develops with: short-acting opioids (heroin, morphine, oxycodone, hydromorphone, fentanyl) — onset 6-12 hours, peak 36-72 hours, duration 5-7 days; long-acting opioids (methadone, sustained-release formulations) — onset 24-48 hours, peak 4-7 days, duration 14-21 days; ultra-short acting (fentanyl analogs) — onset 4-6 hours. Severity assessed by Clinical Opiate Withdrawal Scale (COWS): mild 5-12, moderate 13-24, moderately severe 25-36, severe >36. Subjective Opiate Withdrawal Scale (SOWS) for patient self-report.

Pathophysiology: chronic opioid receptor stimulation (μ-opioid primarily) causes downregulation, decreased intracellular cAMP, adaptations in locus coeruleus (LC) suppressing noradrenergic activity. With abrupt cessation, LC neurons rebound with hyperactivity causing sympathetic surge (sweating, tachycardia, hypertension, mydriasis, piloerection 'goose flesh', lacrimation, rhinorrhea, hyperthermia, restlessness). Additional mechanisms include altered glutamatergic, GABAergic, dopaminergic systems, dynorphin/kappa-opioid contributing to dysphoria, HPA axis activation. Symptoms: early/mild — anxiety, restlessness, drug craving, lacrimation, rhinorrhea, yawning, sweating; moderate — dilated pupils, gooseflesh, muscle aches, abdominal cramps, tremor; severe — bone/joint pain, hot/cold flashes, nausea, vomiting, diarrhea, insomnia, agitation, dysphoria, hypertension, tachycardia, fever, anorexia, weight loss, fatigue, depression, suicidal ideation, autonomic instability.

Clinical management: assessment of severity (COWS), evaluation for medical comorbidities (HIV, HCV, endocarditis, abscesses, pneumonia in IV drug users, electrolyte disturbances from diarrhea/vomiting), pregnancy testing in women, mental health assessment. Treatment goals: relieve symptoms, prevent complications, transition to medication-assisted treatment (MAT) for opioid use disorder. First-line treatment is opioid agonist therapy: buprenorphine (partial agonist) — induction once moderate withdrawal (COWS ≥12) to avoid precipitating withdrawal, sublingual formulations 4-8 mg initial then titrating to 8-24 mg/day stabilization, low-dose induction protocols (Bernese method, microdosing) for fentanyl/methadone transitions; methadone (full agonist) — only in licensed opioid treatment programs (OTPs) for opioid use disorder, 20-30 mg initial then titrating to 60-120 mg stabilization. Alpha-2 agonists for symptom control: lofexidine (Lucemyra — FDA-approved 2018) 0.54 mg every 5-6 hours up to 2.88 mg/day, clonidine 0.1-0.3 mg every 4-6 hours (off-label). Adjunctive medications: ondansetron or prochlorperazine for nausea, loperamide for diarrhea, NSAIDs or acetaminophen for myalgias, hydroxyzine or promethazine for anxiety/insomnia, trazodone or melatonin for insomnia, tizanidine or methocarbamol for muscle spasms. Avoid benzodiazepines if possible due to CNS depression risk. IV fluids and electrolytes for severe symptoms. Inpatient detoxification for severe withdrawal, complicated medical comorbidities, pregnancy. Critical: post-detox transition to MAT (buprenorphine maintenance, methadone maintenance, naltrexone — extended-release injectable XR-NTX requires 7-10 day opioid-free period before initiation), behavioral therapy, counseling. Without MAT, relapse rates >90%, with significant overdose risk due to lost tolerance.